New Antidepressant Agent with Approval

Vortioxetine, an agent with antagonistic and agonistic serotonergic activity in rats data (www.ncbi.nlm.nih.gov/pubmed/22171087) has been approved by the FDA for treatment of major depressive disorder in the U.S.  (www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370416.htm) and also the Committee for Medicinal Products for Human Use gave a marketing authorization for the European market (www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002717/WC500153088.pdf).
Clinical trials showed a superior effect on depressive symptoms of vortioxetine in comparison to placebo (e.g. www.ncbi.nlm.nih.gov/pubmed/22901346 or www.ncbi.nlm.nih.gov/pubmed/22572889) as well as a lack of difference between vortioxetine and placebo (e.g. www.ncbi.nlm.nih.gov/pubmed/23252878 or www.ncbi.nlm.nih.gov/pubmed/22963932).

Vortioxetine has been reported to have positive effects on cognition (www.ncbi.nlm.nih.gov/pubmed/22572889) and did further not impair psychomotor reaction e.g. during driving in comparison to mirtazapine (www.ncbi.nlm.nih.gov/pubmed/23588319).

Interestingly, vortioxetine administration in the rat was paralleled by an increase of EEG power while administration of escitalopram and duloxetine were not (www.sciencedirect.com/science/article/pii/S0924933813760346).

Since there are currently no studies avalable thatstudied EEG alterations in humans  associated with vortioxetine, further research should use electrophysiological methods to shed more light on the mode of action of this new agent.


Posted on 6 jan 2014

News



Abstract Book available

 The complete Abstract Book for the Zurich 2018 Meeting is available now

...
Read more

Final Program

The final program for the IPEG Meeting November 21st-25th in Zurich is ready for download HERE

...
Read more

Preliminary Programm ZURICH IPEG Meeting 2018

Preliminary Program of 2018 IPEG Meeting is available now!

See here

or download here

...
Read more